<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820673</url>
  </required_header>
  <id_info>
    <org_study_id>M-24001-40</org_study_id>
    <nct_id>NCT04820673</nct_id>
  </id_info>
  <brief_title>Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)</brief_title>
  <acronym>PROSES</acronym>
  <official_title>A Real-world Prospective Cohort Study of Patients With Moderate to Severe Acne Vulgaris Treated With Sarecycline (Seysara®) In Community Practice Settings in the U.S</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of&#xD;
      health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with&#xD;
      moderate to severe non-nodular AV who are administered sarecycline (Seysara®) in real-world&#xD;
      community practice settings in the United States (U.S). Investigator's Global Assessment&#xD;
      (IGA) of AV and safety measures associated with use of sarecycline (Seysara®) will be&#xD;
      assessed over the study observation period of 12 weeks. Clinicians will prescribe sarecycline&#xD;
      (Seyara®) as per their own clinical judgment and standard practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Acne Symptom and Impact Scale Questionnaire (ASIS) for PROs Assessment</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Facial IGA success at Week 12, defined as a 2-point decrease in IGA score from baseline and a score of 0 (clear) or 1 (almost clear).</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Sarecycline</arm_group_label>
    <description>Eligible patients prescribed with commercially available sarecycline will be followed-up for 12 weeks post-initiation of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarecycline</intervention_name>
    <description>Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.</description>
    <arm_group_label>Sarecycline</arm_group_label>
    <other_name>Seysara®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate to severe non-nodular acne vulgaris who are on prescribed&#xD;
        sarecycline will be enrolled. Caregivers of eligible pediatric patients will also be&#xD;
        enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 9 years and above&#xD;
&#xD;
          -  Has facial non-nodular AV with IGA score of moderate or severe&#xD;
&#xD;
          -  Considered as a potential candidate for sarecycline (Seysara®) treatment, per&#xD;
             clinician judgment&#xD;
&#xD;
        Caregiver Inclusion Criteria:&#xD;
&#xD;
          -  Primary caregiver of the study-eligible patient&#xD;
&#xD;
          -  Male or female, aged 18 years and above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any known resistance to other tetracyclines&#xD;
&#xD;
          -  Patients with any dermatological or physical condition of the face that could&#xD;
             interfere with the AV clinical evaluations.&#xD;
&#xD;
          -  Patients with any history of allergy to tetracycline-class antibiotics,&#xD;
             pseudomembranous colitis or antibiotic-associated colitis.&#xD;
&#xD;
          -  Unable to comply with the requirements of the study or patients who in the opinion of&#xD;
             the Site Investigator should not participate in the study&#xD;
&#xD;
        Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Almirall, S.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Èric Massana</last_name>
    <phone>0034 932 913 986</phone>
    <email>eric.massana@almirall.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Almirall Site#2</name>
      <address>
        <city>Woodhaven</city>
        <state>Michigan</state>
        <zip>48183</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Almirall Site #1</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prospective</keyword>
  <keyword>Non-nodular Acne Vulgaris</keyword>
  <keyword>Perceptions</keyword>
  <keyword>Health-Related Quality of Life (HRQoL)</keyword>
  <keyword>Patient-Reported Outcomes (PROs)</keyword>
  <keyword>Signs &amp; Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarecycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

